A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women.

Trial Profile

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of SCE-B on Nocturnal Vasomotor Symptoms in Postmenopausal Women.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2013

At a glance

  • Drugs Conjugated estrogens (Primary)
  • Indications Hot flashes; Menopausal syndrome
  • Focus Biomarker; Therapeutic Use
  • Sponsors Duramed Pharmaceuticals Inc
  • Most Recent Events

    • 01 Jan 2012 Results published in Obstetrics and Gynecology.
    • 19 May 2010 Results were published at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 18 May 2010 Primary endpoint results were presented today at the 58th Annual Clinical Meeting of the American College of Obstetrics and Gynaecologists, as reported in a Teva Womens Health Inc media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top